A Phase 2 interventional study of BNT162b2 and Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) in SARS-CoV-2 Infection, COVID-19 and SARS-CoV-2 Acute Respiratory Disease, sponsored by BioNTech SE. Completed at 35 sites in 4 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-22.
Sponsored by BioNTech SE · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 9th largest by enrollment, is one of 30 that started in 2021, is one of 16 in phase 2, and was the 21st registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,380 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 12th largest by enrollment, is one of 10 that started in 2021, is one of 6 in phase 2, and was the 20th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This trial consisted of three parts, Part A, Part B, and Part C, and evaluated the safety and immunogenicity of a third (booster) injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and immunogenicity of a third booster injection of the monovalent vaccine BNT162b2 (B.1.617.2) or BNT162b2 (B.1.1.7), in participants who had received two doses of the parent vaccine BNT162b2 at 30 µg, at least 6 months after the second dose of BNT162b2. It also evaluated the safety and immunogenicity of a three-dose regimen of BNT162b2 (B.1.1.7 + B.1.617.2) in participants who had not received prior Coronavirus Disease 2019 (COVID-19) vaccination. In addition, the safety and immunogenicity of BNT162b2 (B.1.1.529.1) or BNT162b2 given as a third or fourth vaccine dose to RNA COVID-19 vaccine-experienced participants with history of SARS-CoV-2 Omicron variant infection was evaluated and contrasted with the natural immune response reached after infection with the SARS-CoV-2 Omicron variant in RNA COVID-19 vaccine-experienced participants.
Trial participants in Part A were assigned to one of 6 cohorts (Cohort 1-6). Trial participants in Part B were assigned to one of 3 cohorts (Cohort 1, 4, and 6). Trial participants in Part C were randomized in a 2:2:1 ratio into 3 cohorts (Cohort 7-9).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
Biological: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Participants received 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
Biological: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Participants received1 dose of BNT162b2 (B.1.1.7) of 30 µg.
Biological: Monovalent BNT162b2 (B.1.1.7)
Participants received 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
Biological: Monovalent BNT162b2 (B.1.617.2)
Participants received 1 dose of BNT162b2 of 30 µg.
Biological: BNT162b2
Participants received 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
Biological: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Participants received 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
Biological: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Participants received 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
Biological: Monovalent BNT162b2 (B.1.617.2)
Participants received 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
Biological: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Participants received 1 dose of BNT162b2 (B.1.1.529.1) of 30 µg.
Biological: Monovalent BNT162b2 (B.1.1.529.1)
Participants received 1 dose of BNT162b2 of 30 µg.
Biological: BNT162b2
Participants received no vaccination within 3 months after Visit 1.
Other: Observational
Intramuscular (IM)
Intramuscular (IM)
Intramuscular (IM)
Intramuscular (IM)
Intramuscular (IM)
No vaccination within 3 months after Visit 1.
All Parts - Percentage of Participants Reporting Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling)
Local reactions of any grade are reported. Local reactions were graded using criteria based on the US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of systemic reactions was based on the participant's assessments collected in the electronic diary (e-diary) or mapped from the adverse event case report form from Day 1 to Day 7 after each IMP dose. For Erythema/redness and Induration/swelling, the reported size had to be at least 2.5 cm to be deemed as a local reaction. Local reactions with a size less than 2.5 cm are not included in the analysis. Subjects in Cohort 9 did not receive a vaccination and are not included in this analysis.
Time frame: from Day 1 to Day 7 after each IMP dose
All Parts - Percentage of Participants Reporting Systemic Events (Fever, Fatigue, Headache, Chills, Vomiting, Nausea, Diarrhea, New or Worsened Muscle Pain, and New or Worsened Joint Pain)
Systemic reactions of any grade are reported. Systemic reactions were graded using criteria based on the guidance given in the US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of systemic reactions was based on the participant's assessments collected in the e-diary or mapped from the adverse event case report form from Day 1 to Day 7 after each IMP dose. For Fever, the reported oral temperature had to be ≥38.0°C to be deemed as a systemic event. Oral temperature less than 38.0°C are not included in the analysis. Subjects in Cohort 9 did not receive a vaccination and are not included in this analysis.
Time frame: from Day 1 to Day 7 after each IMP dose
All Parts - Percentage of Participants Reporting Adverse Events (AEs)
An AE is defined as TEAE if the event onset date and time is after the first IMP dose (if the event was absent before the first administration of the IMP) or worsened after the first IMP dose (if the event was present before the first administration of the IMP). In the event of an incomplete onset date, the event is considered as treatment-emergent unless the partial onset date information or complete or partial end date confirms the onset date or the event end prior to the first dose of IMP. Percentages for dose 1, dose 2, dose 3 and overall summaries are based upon the number of participants who received the respective IMP dose.
Time frame: Dose 1 up to 1 month after each dose (all parts)
All Parts - Percentage of Participants Reporting Serious Adverse Events (SAEs)
An SAE was any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/ incapacity; was a congenital anomaly/birth defect and/or was another important medical event. SAEs from dose 1 up to 6 months post last IMP dose are presented. MedDRA (version 26.1) coding dictionary applied. An SAE is defined as TESAE if the event onset date and time is after the first IMP dose (if the event was absent before the first administration of the IMP) or worsened after the first IMP dose (if the event was present before the first administration of the IMP). In the event of an incomplete onset date, the event is considered as treatment-emergent unless the partial onset date information or complete or partial end date confirms the onset date or the event end prior to the first dose of IMP.
Time frame: Dose 1 up to 6 months after the last dose
Part B - GMR of B.1.1.7 NT 1 Month After 1 Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the Phase III C4591001 (NCT04368728) Trial
GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of least square means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and vaccine group. The overall number of participants analyzed represents the number of participants with valid and determinate assay results for B.1.1.7 and reference strain respectively at the given dose/sampling time point within the specified window. GMR data are presented below as per the primary endpoint defined in the protocol. GMTs for the individual arms (from which GMR was derived) were secondary endpoints and are presented in outcome measure 22. GMR = Geometric mean ratio; NT = neutralizing titers
Time frame: 1 month after booster dose in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - GMR of B.1.617.2 NT 1 Month After 1 Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the Phase III C4591001 (NCT04368728) Trial
GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of least square means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. The overall number of participants analyzed represents the number of participants with valid and determinate assay results for B.1.617.2 and reference strain respectively at the given dose/sampling time point within the specified window. GMR data are presented below as per the primary endpoint defined in the protocol. GMTs for the individual arms (from which GMR was derived) were secondary endpoints and are presented in outcome measure 22. GMR = Geometric mean ratio; NT = neutralizing titers
Time frame: 1 month after booster dose in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - GMR of B.1.617.2 NT 1 Month After 1 Dose of BNT162b2 (B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the Phase III C4591001 (NCT04368728) Trial
GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of least square means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. The overall number of participants analyzed represents the number of participants with valid and determinate assay results for B.1.617.2 and reference strain respectively at the given dose/sampling time point within the specified window. GMR data are presented below as per the primary endpoint defined in the protocol. GMTs for the individual arms (from which GMR was derived) were secondary endpoints and are presented in outcome measure 24.
Time frame: 1 month after booster dose in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - Difference in Seroresponse (SR) to B.1.1.7 NT 1 Month After 1 Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From C4591001 (NCT04368728)
Seroresponse was defined as a ≥4-fold rise in neutralizing titer from baseline. For subjects with a baseline titer less than the lower limit of quantitation (\<LLOQ), seroresponse was defined as a post-vaccination titer of ≥4× LLOQ. Adjusted difference was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. Associated 2-sided 95% CI based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in seroresponse data are presented below as per the primary endpoint defined in the protocol. Seroresponses for the individual arms (from which the difference was derived) were secondary endpoints and are presented in outcome measure 23.
Time frame: 1 month after booster dose in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - Difference in SR to B.1.617.2 NT 1 Month After 1 Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From C4591001 (NCT04368728)
Seroresponse was defined as a ≥4-fold rise in neutralizing titer from baseline. For subjects with a baseline titer less than the lower limit of quantitation (\<LLOQ), seroresponse was defined as a post-vaccination titer of ≥4× LLOQ. Adjusted difference was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. Associated 2-sided 95% CI based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in seroresponse data are presented below as per the primary endpoint defined in the protocol. Seroresponses for the individual arms (from which the difference was derived) were secondary endpoints and are presented in outcome measure 23.
Time frame: 1 month after booster dose in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - Difference in SR to B.1.617.2 NT 1 Month After 1 Dose of BNT162b2 (B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From C4591001 (NCT04368728)
Seroresponse was defined as a ≥4-fold rise in neutralizing titer from baseline. For subjects with a baseline titer less than the lower limit of quantitation (\<LLOQ), seroresponse was defined as a post-vaccination titer of ≥4× LLOQ. Adjusted difference was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. Associated 2-sided 95% CI based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in seroresponse data are presented below as per the primary endpoint defined in the protocol. Seroresponses for the individual arms (from which the difference was derived) were secondary endpoints and are presented in outcome measure 25.
Time frame: 1 month after booster dose in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - GMR of B.1.1.7 NT 1 Month After 2 Doses of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 Vaccine-naïve Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the C4591001 (NCT04368728) Trial
Cohort B6 aimed to generate data to support a 2-dose primary regimen of alpha-delta multivalent BNT162b2 vaccine in SARS-CoV-2 naïve, unvaccinated individuals. The population recruited in Cohort B6, while complying with the inclusion criterium of no known history SARS-CoV-2 infection, were retrospectively seropositive for SARS-CoV-2 by planned N-binding antibody assessment of baseline samples. While the cohort was COVID-19 vaccine-naïve, it was not SARS-CoV-2-naïve as needed to match the control group (C4591001/NCT04368728). Procedurally, submission of a protocol amendment was not possible. However, the Statistical Analysis Plan was amended to describe that the non-inferiority analysis could not be performed according to the protocol. Control participants were not selected as planned; therefore, data were not available to calculate the GMR. Available GMT data for the 17 Cohort B6 participants without evidence of infection were analyzed and are presented in Outcome Measure 28.
Time frame: 1 month
Part B - GMR of B.1.617.2 NT 1 Month After 2 Doses of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 Vaccine-naïve Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the C4591001 (NCT04368728) Trial
Cohort B6 aimed to generate data to support a 2-dose primary regimen of alpha-delta multivalent BNT162b2 vaccine in SARS-CoV-2 naïve, unvaccinated individuals. The population recruited in Cohort B6, while complying with the inclusion criterium of no known history SARS-CoV-2 infection, were retrospectively seropositive for SARS-CoV-2 by planned N-binding antibody assessment of baseline samples. While the cohort was COVID-19 vaccine-naïve, it was not SARS-CoV-2-naïve as needed to match the control group (C4591001/NCT04368728). Procedurally, submission of a protocol amendment was not possible. However, the Statistical Analysis Plan was amended to describe that the non-inferiority analysis could not be performed according to the protocol. Control participants were not selected as planned; therefore, data were not available to calculate the GMR. Available GMT data for the 17 Part B Cohort 6 participants without evidence of infection were analyzed and are presented in Outcome Measure 28.
Time frame: 1 month
Part B - The Difference in SR to B.1.1.7 NT 1 Month After 2 Doses of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 Vaccine-naïve Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the C4591001 (NCT04368728) Trial
Cohort B6 aimed to generate data to support a 2-dose primary regimen of alpha-delta multivalent BNT162b2 vaccine in SARS-CoV-2 naïve, unvaccinated individuals. The population recruited in Cohort B6, while complying with the inclusion criterium of no known history SARS-CoV-2 infection, were retrospectively seropositive for SARS-CoV-2 by planned N-binding antibody assessment of baseline samples. While the cohort was COVID-19 vaccine-naïve, it was not SARS-CoV-2-naïve as needed to match the control group (C4591001/NCT04368728). Procedurally, submission of a protocol amendment was not possible. However, the Statistical Analysis Plan was amended to describe that non-inferiority analysis could not be performed according to the protocol. Control participants were not selected as planned; therefore, data were not available to calculate difference in SR. Available SR data for the 17 Part B Cohort 6 participants without evidence of infection were analyzed and presented in Outcome Measure 31.
Time frame: 1 month
Part B - The Difference in SR to B.1.617.2 NT 1 Month After 2 Doses of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 Vaccine-naïve Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the C4591001 (NCT04368728) Trial
Cohort B6 aimed to generate data to support a 2-dose primary regimen of alpha-delta multivalent BNT162b2 vaccine in SARS-CoV-2 naïve, unvaccinated individuals. The population recruited in Cohort B6, while complying with the inclusion criterium of no known history SARS-CoV-2 infection, were retrospectively seropositive for SARS-CoV-2 by planned N-binding antibody assessment of baseline samples. While the cohort was COVID-19 vaccine-naïve, it was not SARS-CoV-2-naïve as needed to match the control group (C4591001/NCT04368728). Procedurally, submission of a protocol amendment was not possible. However, the Statistical Analysis Plan was amended to describe that the non-inferiority analysis could not be performed according to the protocol. Control participants were not selected as planned; therefore data were not available to calculate difference in SR. Available SR data for the 17 Part B Cohort 6 participants without evidence of infection were analyzed and presented in Outcome Measure 31.
Time frame: 1 month
Part B - GMR of Reference Strain NT After One Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in Participants With Evidence of Prior Infection to the Reference Strain NT After 2 Doses of BNT162b2 in Participants Without Evidence of Infection
GMR of reference strain NT 3 weeks (3W) after one dose (PD1) of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection to the reference strain NT 1 month after two doses of BNT162b2 in participants without evidence of infection (COVID-19 Vaccine-naïve Participants) from the Phase III trial C4591001 (NCT04368728). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5 × LLOQ. GMTs of NTs are presented in the descriptive data section of this outcome measure. GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of LS means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. GMR data are presented in the statistical analysis section.
Time frame: 3 weeks post Dose 1 in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - The Difference in SRs to the Reference Strain NT in Subjects With Evidence of Prior Infection and to the Reference Strain NT in Participants Without Evidence of Infection (COVID-19 Vaccine-naïve Participants)
The difference in SRs to the reference strain NT 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection to the reference strain NT 1 month after two doses of BNT162b2 in participants without evidence of infection from the Phase III trial C4591001 (NCT04368728). SR was defined as achieving a ≥4-fold rise from baseline. If the baseline measurement was below the LLOQ, a post-vaccination assay result ≥4 × LLOQ was considered a SR. SR to the reference strain NTs are presented in the descriptive data section of this outcome measure. Adjusted difference in proportions was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. 2-Sided CI was based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in SR data are presented in the statistical analysis section.
Time frame: 3 weeks post Dose 1 in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part C - GMR of B.1.1.529.1 NT 1 Month After One Dose of BNT162b2 (B.1.1.529.1) in RNA-based COVID-19 Vaccine-experienced Participants With History of SARS-CoV-2 Infection to Those at 1 Month After One Dose of BNT162b2 for Cohorts 7 and 8.
GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of least square means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age and number of prior doses. The overall number of participants analyzed represents the number of participants with valid and determinate assay results for B.1.1.529.1 at the given dose/sampling time point within the specified window. GMR data are presented below as per the primary endpoint defined in the protocol. GMTs for the individual arms (from which the difference was derived) were secondary endpoints and are presented in outcome measure 32.
Time frame: 1 month after 1 dose of BNT162b2 or BNT162b2 (B.1.1.529.1)
Part C - The Difference in SR of B.1.1.529.1 NT 1 Month After One Dose of BNT162b2 (B.1.1.529.1) in RNA-based COVID-19 Vaccine-experienced Participants With History of SARS-CoV-2 Infection to Those at 1 Month After One Dose of BNT162b2 for Cohorts 7 & 8.
SR was defined as a ≥4-fold rise in neutralizing titer from baseline. For participants with a baseline titer less than the lower limit of quantitation (\<LLOQ), SR was defined as a post-vaccination titer of ≥4× LLOQ. SR to the reference strain NTs are presented in the descriptive data section of this outcome measure. Adjusted difference was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. Associated 2-sided 95% CI were based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in SR data are presented in the statistical analysis section.
Time frame: 1 month after 1 dose of BNT162b2 or BNT162b2 (B.1.1.529.1)
Part A - Geometric Mean Titer (GMT) at Each Timepoint
For BNT162b2-experienced participants (defined as participants who have previously received two injections of 30 μg BNT162b2). Reference and variant(s) of concern (VOC) specific NT. GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ. Cohorts 1, 3, 4 and 5 received only 1 dose of IMP. Cohort 2 received dose 2 on Day 56 and did not receive dose 3. Cohort 6 received dose 2 on Day 21 and received dose 3 approximately 6 months after dose 2.
Time frame: Day 1 up to Day 421
Part A - Geometric Mean Fold Rises (GMFR) From Before Vaccination to Each Subsequent Time Point After Vaccination
For BNT162b2-experienced participants (defined as participants who have previously received two injections of 30 μg BNT162b2). Reference and VOC specific NT. GMFR is calculated as the mean of the difference of logarithmically transformed neutralization titers or antibody levels (later result minus earlier result) and exponentiating the mean. The associated 2-sided 95% CIs are obtained by constructing CIs using Student's t-distribution for the mean difference on the natural log scale and exponentiating the confidence limits. Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ. Cohorts 1, 3, 4 and 5 received only 1 dose of IMP. Cohort 2 received dose 2 on Day 56 and did not receive dose 3. Cohort 6 received dose 2 on Day 21 and received dose 3 approximately 6 months after dose 2.
Time frame: Day 1 to Day 421
Part A - Percentage of Participants Achieving SR in Terms of NT at Each Post Vaccination Time Point
For BNT162b2-experienced participants (defined as participants who have previously received two injections of 30 μg BNT162b2). Reference and VOC specific NT. SR is defined as a ≥4-fold rise in neutralizing titer from baseline (pre IMP dose 1). For subjects with a baseline titer less than the LLOQ, SR is defined as a post-vaccination titer of ≥4 × LLOQ. Pre IMP dose 2 is also 2 months post dose 1 for Cohort 2 and 3 weeks post dose 1 for Cohort 6. Cohorts 1, 3, 4 and 5 received only 1 dose of IMP. Cohort 2 received dose 2 on Day 56 and did not receive dose 3. Cohort 6 received dose 2 on Day 21 and received dose 3 approximately 6 months after dose 2.
Time frame: Day 1 to Day 421
Part B - GMT of VOCs and Reference Strains in Part B Cohort 1 and Control
GMTs of VOCs (B.1.1.7 and B.1.617.2) and reference strain 1 month after 1 dose of BNT162 (B.1.1.7+B.1.167.2) in participants from Part B Cohort 1 of the BNT162-17 trial (BNT162b2-experienced participants), and reference strain 1 month after 2 doses of BNT162b2 in selected participants from the Phase III C4591001 (NCT04368728) trial. GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ.
Time frame: 1 month after booster dose in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - SR of of VOCs and Reference Strains in Part B Cohort 1 and Control
Percentage of participants achieving SR at 1 month after 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants (Cohort 1) and 1 month after 2 doses of BNT162b2 primary series (participants from C4591001 \[NCT04368728\]). SR is defined as a ≥4-fold rise in neutralizing titer from baseline (pre IMP dose 1). For participants with a baseline titer less than the LLOQ, SR is defined as a post-vaccination titer of ≥4 × LLOQ.
Time frame: 1 month after Dose 1 in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - GMT of VOCs and Reference Strains in Part B Cohort 4 and Control
GMTs of VOCs (B.1.617.2) and reference strain 1 month after 1 dose of BNT162 (B.1.167.2) in participants from Part B Cohort 4 of the BNT162-17 trial (BNT162b2-experienced participants), and 1 month after 2 doses of BNT162b2 in selected participants from the Phase III C4591001 (NCT04368728) trial. GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ.
Time frame: 1 month after booster dose in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - SR of of VOCs and Reference Strains in Part B Cohort 4 and Control
Percentage of participants achieving SR at 1 month after 1 dose of BNT162b2 (B.1.617.2) in BNT162b2-experienced subjects (Part B - Cohort 4) and 1 month after 2 doses of BNT162b2 primary series (participants from C4591001 \[NCT04368728\]). SR is defined as a ≥4-fold rise in neutralizing titer from baseline (pre IMP dose 1). For participants with a baseline titer less than the LLOQ, SR is defined as a post-vaccination titer of ≥4 × LLOQ.
Time frame: 1 month after Dose 1 in BNT162-17 participants and 1 month post Dose 2 in participants from the C4591001 (NCT04368728) trial
Part B - GMT of VOCs and Reference Strain in Part B Cohort 6 1 Month After Dose 2 and 1 Month After Dose 3
GMTs of VOCs and reference strain NT 1 month after dose 2 and dose 3 of BNT162b2 (B.1.1.7 + B.1.617.2) (Part B - Cohort 6). GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ.
Time frame: 1 month after Dose 2 and 1 month after Dose 3
Part B - Cohort 6 - Percentages With SRs to VOCs (B.1.1.7, B.1.617.2) and Reference Strain
Percentage of participants achieving SR to VOCs (B.1.1.7, B.1.617.2) and reference strain at 1 month after dose 2 and dose 3 of BNT162b2 (B.1.1.7 + B.1.617.2) (Part B - Cohort 6). SR is defined as a ≥4-fold rise in neutralizing titer from baseline (pre IMP dose 1). For participants with a baseline titer less than the LLOQ, SR is defined as a post vaccination titer of ≥4 × LLOQ. Pre IMP dose 2 is also 3 weeks post dose 1 for Cohort 6.
Time frame: 1 month after Dose 2 and 1 month after Dose 3
Part B - GMTs of VOC in COVID-19 Vaccine-naïve Participants With and Without Evidence of Prior Infection in Part B C6 (1 and 2 Primary Doses Respectively) and in BNT162b2-Experienced Participants Without Evidence of Infection in Part B C1 (1 Booster Dose)
GMTs of VOC specific NTs (B.1.1.7, B.1.617.2, B.1.1.529.5 \[Omicron BA.5\]) 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection (Cohort 6), 1 month after two doses of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants without evidence of infection (Cohort 6), and 1 month after one booster dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants without evidence of infection (Cohort 1). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ; assay results above the ULOQ were set to ULOQ.
Time frame: Day 1 up to 1 month after 1 booster dose in Part B Cohort 1 without evidence of infection, up to 1 month after 2 doses in Part B Cohort 6 without evidence of infection and up to 3 weeks after 1 dose in Part B Cohort 6 with evidence of prior infection
Part B - GMRs of VOC in COVID-19 Vaccine-naïve Participants With and Without Evidence of Prior Infection (1 and 2 Primary Doses Respectively) and in BNT162b2-Experienced Participants Without Evidence of Infection (1 Booster Dose)
GMR of VOC specific NTs (B.1.1.7, B.1.617.2, B.1.1.529.5 \[Omicron BA.5\]) 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection (Cohort 6) to the VOCs NTs 1 month after two doses of BNT162b2 (B.1.1.7 + B.1.617.2) in participants without evidence of infection (Cohort 6), and to the VOCs NTs 1 month after one booster dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants without evidence of infection (Cohort 1). GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of the LS means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. A separate model was fit for each comparison. Assay results below the LLOQ were set to 0.5 × LLOQ; assay results above the ULOQ were set to ULOQ.
Time frame: Day 1 to Day 29
Part B - Difference in SRs to VOCs in COVID-19 Vaccine-naïve Participants With and Without Evidence of Prior Infection (1 and 2 Primary Doses Respectively) and in BNT162b2-Experienced Participants Without Evidence of Infection (1 Booster Dose)
The difference in SRs to VOC specific NTs (B.1.1.7, B.1.617.2, B.1.1.529.5 \[Omicron BA.5\]) 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection (Cohort 6) to those 1 month after two doses of BNT162b2 (B.1.1.7 + B.1.617.2) in participants without evidence of infection (Cohort 6), and to those 1 month after one booster dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants without evidence of infection (Cohort 1). Adjusted difference in proportions estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. 2-Sided CI based on the Newcombe method stratified by sex and age group (18 to 55 years, 56 to 85 years) with minimum risk weights for the difference in proportions.
Time frame: Day 1 to Day 29
Part B - SR of VOC in COVID-19 Vaccine-naïve Participants With and Without Evidence of Prior Infection (1 and 2 Primary Doses Respectively) and in BNT162b2-Experienced Participants Without Evidence of Infection (1 Booster Dose)
SRs of VOC specific NTs (B.1.1.7, B.1.617.2, B.1.1.529.5 \[Omicron BA.5\]) 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection (Cohort 6) 1 month after two doses of BNT162b2 (B.1.1.7 + B.1.617.2) in participants without evidence of infection (Cohort 6), and 1 month after one booster dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants without evidence of infection (Cohort 1). Seroresponse was defined as achieving a ≥4-fold rise from baseline. If the baseline measurement was below the LLOQ, a postvaccination assay result ≥4 × LLOQ was considered a seroresponse.
Time frame: 3 weeks after one dose in participants with evidence of prior infection (Cohort 6), 1 month after two doses in participants without evidence of infection (Cohort 6), and 1 month after one booster dose (Cohort 1)
Part C - GMT - B.1.1.529.1 in RNA Based COVID-19 Vaccine-experienced Participants With History of SARS-CoV-2 Infection
VOC NT in RNA-based COVID-19 vaccine-experienced participants with history of SARS-CoV-2 infection at baseline and 7 days, 1 month, and 3 months after the trial start for Cohorts 7, 8, and 9, and 6 and 12 months after the trial start for Cohorts 7 and 8. GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ. Number of subjects with valid and determinate assay results for the specified variant at the given dose/sampling time point. No vaccination was given to Cohort 9 participants within 3 months after Visit 1. The term "post IMP" does not apply for Cohort 9 since no IMP was given, but blood was collected at the same timepoints post randomization.
Time frame: Day 1 to Day 360
Adult male and female participants were eligible if they had received two doses of the parent vaccine BNT162b2 at 30 µg, and the second dose of BNT162b2 was at least 6 months ago (Part A Cohorts 1 to 5, Part B Cohorts 1 and 4), or had not received prior Coronavirus Disease 2019 (COVID-19) vaccination (Part A Cohort 6, Part B Cohort 6) or had received 2 or 3 injections of any authorized COVID-19 RNA-based vaccine and were subsequently diagnosed with SARS-CoV-2 infection from January 2022 onwards
| Milestone | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 21 | 20 | 20 | 20 | 42 | 17 | 349 | 352 | 361 | 72 | 71 | 35 |
| Completed | 14 | 10 | 15 | 12 | 29 | 13 | 280 | 291 | 299 | 60 | 55 | 30 |
| Not completed | 7 | 10 | 5 | 8 | 13 | 4 | 69 | 61 | 62 | 12 | 16 | 5 |
| Withdrew: Withdrawal of consent | 0 | 0 | 1 | 3 | 3 | 0 | 30 | 9 | 3 | 2 | 5 | 1 |
| Withdrew: Lost to follow-up | 2 | 4 | 2 | 3 | 5 | 2 | 15 | 12 | 38 | 6 | 6 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 7 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 2 | 2 | 4 | 2 | 4 | 22 | 8 | 1 | 3 | 2 |
| Withdrew: Protocol violation | 2 | 3 | 0 | 0 | 1 | 0 | 16 | 18 | 2 | 2 | 2 | 1 |
| Withdrew: Not further specified | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 1 |
Local reactions of any grade are reported. Local reactions were graded using criteria based on the US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of systemic reactions was based on the participant's assessments collected in the electronic diary (e-diary) or mapped from the adverse event case report form from Day 1 to Day 7 after each IMP dose. For Erythema/redness and Induration/swelling, the reported size had to be at least 2.5 cm to be deemed as a local reaction. Local reactions with a size less than 2.5 cm are not included in the analysis. Subjects in Cohort 9 did not receive a vaccination and are not included in this analysis.
| Participants | Part A - Cohort 1: 1 Dose of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any local reaction - Overall | 19 | 20 | 17 | 19 | 37 | 15 | 290 | 310 | 261 | 63 | 61 | — |
| Pain at the injection site - Overall | 17 | 19 | 14 | 17 | 27 | 13 | 254 | 264 | 247 | 57 | 52 | — |
| Tenderness - Overall | 18 | 20 | 17 | 18 | 33 | 14 | 220 | 273 | 201 | 55 | 56 | — |
| Erythema/redness - Overall | 1 | 3 | 1 | 1 | 8 | 1 | 34 | 30 | 47 | 11 | 7 | — |
| Induration/swelling - Overall | 1 | 3 | 1 | 2 | 10 | 4 | 36 | 30 | 58 | 8 | 5 | — |
| Any local reaction - After IMP Dose 1 | 19 | 20 | 17 | 19 | 37 | 12 | 290 | 310 | 213 | 63 | 61 | — |
| Pain at the injection site - After IMP Dose 1 | 17 | 19 | 14 | 17 | 27 | 10 | 254 | 264 | 194 | 57 | 52 | — |
| Tenderness - After IMP Dose 1 | 18 | 20 | 17 | 18 | 33 | 12 | 220 | 273 | 133 | 55 | 56 | — |
| Erythema/redness - After IMP Dose 1 | 1 | 3 | 1 | 1 | 8 | 1 | 34 | 30 | 22 | 11 | 7 | — |
| Induration/swelling - After IMP Dose 1 | 1 | 3 | 1 | 2 | 10 | 2 | 36 | 30 | 36 | 8 | 5 | — |
| Any local reaction - After IMP Dose 2 | — | 12 | — | — | — | 10 | — | — | 153 | — | — | — |
| Pain at the injection site - After IMP Dose 2 | — | 11 | — | — | — | 9 | — | — | 142 | — | — | — |
| Tenderness - After IMP Dose 2 | — | 9 | — | — | — | 10 | — | — | 80 | — | — | — |
| Erythema/redness - After IMP Dose 2 | — | 0 | — | — | — | 0 | — | — | 16 | — | — | — |
| Induration/swelling - After IMP Dose 2 | — | 1 | — | — | — | 0 | — | — | 22 | — | — | — |
| Any local reaction - After IMP Dose 3 | — | — | — | — | — | 8 | — | — | 169 | — | — | — |
| Pain at the injection site - After IMP Dose 3 | — | — | — | — | — | 8 | — | — | 153 | — | — | — |
| Tenderness - After IMP Dose 3 | — | — | — | — | — | 7 | — | — | 123 | — | — | — |
| Erythema/redness - After IMP Dose 3 | — | — | — | — | — | 0 | — | — | 19 | — | — | — |
| Induration/swelling - After IMP Dose 3 | — | — | — | — | — | 3 | — | — | 19 | — | — | — |
Systemic reactions of any grade are reported. Systemic reactions were graded using criteria based on the guidance given in the US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"; the guidance uses the Grades 1 (mild), 2 (moderate), 3 (severe), and 4 (potentially life-threatening). The reporting of systemic reactions was based on the participant's assessments collected in the e-diary or mapped from the adverse event case report form from Day 1 to Day 7 after each IMP dose. For Fever, the reported oral temperature had to be ≥38.0°C to be deemed as a systemic event. Oral temperature less than 38.0°C are not included in the analysis. Subjects in Cohort 9 did not receive a vaccination and are not included in this analysis.
| Participants | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any systemic event - Overall | 17 | 20 | 15 | 16 | 33 | 13 | 255 | 267 | 253 | 52 | 55 | — |
| Fever: Oral temperature of ≥ 38.0℃ - Overall | 4 | 5 | 3 | 2 | 0 | 1 | 32 | 34 | 34 | 1 | 3 | — |
| Nausea - Overall | 2 | 9 | 4 | 7 | 4 | 4 | 61 | 64 | 93 | 9 | 15 | — |
| Vomiting - Overall | 0 | 3 | 0 | 1 | 0 | 1 | 8 | 7 | 34 | 1 | 0 | — |
| Diarrhea - Overall | 2 | 5 | 3 | 2 | 6 | 4 | 19 | 39 | 68 | 8 | 10 | — |
| Headache - Overall | 15 | 17 | 12 | 8 | 22 | 10 | 160 | 178 | 190 | 32 | 35 | — |
| Fatigue - Overall | 15 | 19 | 15 | 15 | 30 | 9 | 219 | 220 | 180 | 40 | 44 | — |
| Chills - Overall | 10 | 13 | 3 | 9 | 13 | 7 | 91 | 115 | 77 | 11 | 14 | — |
| New or worsened muscle pain - Overall | 10 | 14 | 10 | 8 | 16 | 8 | 123 | 131 | 143 | 20 | 19 | — |
| New or worsened joint pain - Overall | 6 | 7 | 4 | 4 | 13 | 5 | 87 | 78 | 101 | 9 | 9 | — |
| Any systemic event - After IMP Dose 1 | 17 | 18 | 15 | 16 | 33 | 11 | 255 | 267 | 203 | 52 | 55 | — |
| Fever: Oral temperature of ≥ 38.0℃ - After IMP Dose 1 | 4 | 4 | 3 | 2 | 0 | 0 | 32 | 34 | 14 | 1 | 3 | — |
| Nausea - After IMP Dose 1 | 2 | 6 | 4 | 7 | 4 | 3 | 61 | 64 | 58 | 9 | 15 | — |
| Vomiting - After IMP Dose 1 | 0 | 1 | 0 | 1 | 0 | 1 | 8 | 7 | 22 | 1 | 0 | — |
| Diarrhea - After IMP Dose 1 | 2 | 4 | 3 | 2 | 6 | 2 | 19 | 39 | 44 | 8 | 10 | — |
| Headache - After IMP Dose 1 | 15 | 16 | 12 | 8 | 22 | 8 | 160 | 178 | 125 | 32 | 35 | — |
| Fatigue - After IMP Dose 1 | 15 | 17 | 15 | 15 | 30 | 8 | 219 | 220 | 119 | 40 | 44 | — |
| Chills - After IMP Dose 1 | 10 | 9 | 3 | 9 | 13 | 3 | 91 | 115 | 43 | 11 | 14 | — |
| New or worsened muscle pain - After IMP Dose 1 | 10 | 12 | 10 | 8 | 16 | 6 | 123 | 131 | 92 | 20 | 19 | — |
| New or worsened joint pain - After IMP Dose 1 | 6 | 6 | 4 | 4 | 13 | 3 | 87 | 78 | 68 | 9 | 9 | — |
| Any systemic event - After IMP Dose 2 | — | 14 | — | — | — | 9 | — | — | 139 | — | — | — |
| Fever: Oral temperature of ≥ 38.0℃ - After IMP Dose 2 | — | 1 | — | — | — | 1 | — | — | 12 | — | — | — |
| Nausea - After IMP Dose 2 | — | 5 | — | — | — | 2 | — | — | 28 | — | — | — |
| Vomiting - After IMP Dose 2 | — | 2 | — | — | — | 1 | — | — | 9 | — | — | — |
| Diarrhea - After IMP Dose 2 | — | 2 | — | — | — | 2 | — | — | 20 | — | — | — |
| Headache - After IMP Dose 2 | — | 11 | — | — | — | 6 | — | — | 88 | — | — | — |
| Fatigue - After IMP Dose 2 | — | 13 | — | — | — | 6 | — | — | 77 | — | — | — |
| Chills - After IMP Dose 2 | — | 6 | — | — | — | 3 | — | — | 29 | — | — | — |
| New or worsened muscle pain - After IMP Dose 2 | — | 9 | — | — | — | 4 | — | — | 61 | — | — | — |
| New or worsened joint pain - After IMP Dose 2 | — | 3 | — | — | — | 4 | — | — | 39 | — | — | — |
| Any systemic event - After IMP Dose 3 | — | — | — | — | — | 6 | — | — | 142 | — | — | — |
| Fever: Oral temperature of ≥ 38.0℃ - After IMP Dose 3 | — | — | — | — | — | 0 | — | — | 13 | — | — | — |
| Nausea - After IMP Dose 3 | — | — | — | — | — | 1 | — | — | 33 | — | — | — |
| Vomiting - After IMP Dose 3 | — | — | — | — | — | 0 | — | — | 12 | — | — | — |
| Diarrhea - After IMP Dose 3 | — | — | — | — | — | 1 | — | — | 22 | — | — | — |
| Headache - After IMP Dose 3 | — | — | — | — | — | 4 | — | — | 104 | — | — | — |
| Fatigue - After IMP Dose 3 | — | — | — | — | — | 4 | — | — | 87 | — | — | — |
| Chills - After IMP Dose 3 | — | — | — | — | — | 2 | — | — | 27 | — | — | — |
| New or worsened muscle pain - After IMP Dose 3 | — | — | — | — | — | 4 | — | — | 54 | — | — | — |
| New or worsened joint pain - After IMP Dose 3 | — | — | — | — | — | 2 | — | — | 28 | — | — | — |
An AE is defined as TEAE if the event onset date and time is after the first IMP dose (if the event was absent before the first administration of the IMP) or worsened after the first IMP dose (if the event was present before the first administration of the IMP). In the event of an incomplete onset date, the event is considered as treatment-emergent unless the partial onset date information or complete or partial end date confirms the onset date or the event end prior to the first dose of IMP. Percentages for dose 1, dose 2, dose 3 and overall summaries are based upon the number of participants who received the respective IMP dose.
| percentage of participants | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any AE after IMP Dose 1 | 19.0 | 30.0 | 30.0 | 15.0 | 66.7 | 29.4 | 14.6 | 13.1 | 20.2 | 12.5 | 19.7 | — |
| Any AE after IMP Dose 2 | — | 27.8 | — | — | — | 17.6 | — | — | 15.7 | — | — | — |
| Any AE after IMP Dose 3 | — | — | — | — | — | 20.0 | — | — | 15.2 | — | — | — |
An SAE was any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/ incapacity; was a congenital anomaly/birth defect and/or was another important medical event. SAEs from dose 1 up to 6 months post last IMP dose are presented. MedDRA (version 26.1) coding dictionary applied. An SAE is defined as TESAE if the event onset date and time is after the first IMP dose (if the event was absent before the first administration of the IMP) or worsened after the first IMP dose (if the event was present before the first administration of the IMP). In the event of an incomplete onset date, the event is considered as treatment-emergent unless the partial onset date information or complete or partial end date confirms the onset date or the event end prior to the first dose of IMP.
| Percentage of participants | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Orginal Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Parts - Percentage of Participants Reporting Serious Adverse Events (SAEs) | 0 | 0 | 0 | 0 | 0 | 0 | 1.1 | 1.7 | 3.6 | 0 | 7.0 | — |
GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of least square means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and vaccine group. The overall number of participants analyzed represents the number of participants with valid and determinate assay results for B.1.1.7 and reference strain respectively at the given dose/sampling time point within the specified window. GMR data are presented below as per the primary endpoint defined in the protocol. GMTs for the individual arms (from which GMR was derived) were secondary endpoints and are presented in outcome measure 22. GMR = Geometric mean ratio; NT = neutralizing titers
| Titer ratio | BNT162-17 Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) / C4591001 BNT162b2 30 μg |
|---|---|
| Part B - GMR of B.1.1.7 NT 1 Month After 1 Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the Phase III C4591001 (NCT04368728) Trial | 8.81 (7.49 to 10.36) |
GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of least square means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. The overall number of participants analyzed represents the number of participants with valid and determinate assay results for B.1.617.2 and reference strain respectively at the given dose/sampling time point within the specified window. GMR data are presented below as per the primary endpoint defined in the protocol. GMTs for the individual arms (from which GMR was derived) were secondary endpoints and are presented in outcome measure 22. GMR = Geometric mean ratio; NT = neutralizing titers
| Titer ratio | BNT162-17 Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) / C4591001 BNT162b2 30 μg |
|---|---|
| Part B - GMR of B.1.617.2 NT 1 Month After 1 Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the Phase III C4591001 (NCT04368728) Trial | 4.88 (4.19 to 5.68) |
GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of least square means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. The overall number of participants analyzed represents the number of participants with valid and determinate assay results for B.1.617.2 and reference strain respectively at the given dose/sampling time point within the specified window. GMR data are presented below as per the primary endpoint defined in the protocol. GMTs for the individual arms (from which GMR was derived) were secondary endpoints and are presented in outcome measure 24.
| Titer ratio | BNT162-17 Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) / C4591001 BNT162b2 30 μg |
|---|---|
| Part B - GMR of B.1.617.2 NT 1 Month After 1 Dose of BNT162b2 (B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From the Phase III C4591001 (NCT04368728) Trial | 6.40 (5.47 to 7.48) |
Seroresponse was defined as a ≥4-fold rise in neutralizing titer from baseline. For subjects with a baseline titer less than the lower limit of quantitation (\<LLOQ), seroresponse was defined as a post-vaccination titer of ≥4× LLOQ. Adjusted difference was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. Associated 2-sided 95% CI based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in seroresponse data are presented below as per the primary endpoint defined in the protocol. Seroresponses for the individual arms (from which the difference was derived) were secondary endpoints and are presented in outcome measure 23.
| percentage difference | BNT162-17 Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) - C4591001 BNT162b2 30 μg |
|---|---|
| Part B - Difference in Seroresponse (SR) to B.1.1.7 NT 1 Month After 1 Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From C4591001 (NCT04368728) | 0.25 (-4.86 to 5.26) |
Seroresponse was defined as a ≥4-fold rise in neutralizing titer from baseline. For subjects with a baseline titer less than the lower limit of quantitation (\<LLOQ), seroresponse was defined as a post-vaccination titer of ≥4× LLOQ. Adjusted difference was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. Associated 2-sided 95% CI based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in seroresponse data are presented below as per the primary endpoint defined in the protocol. Seroresponses for the individual arms (from which the difference was derived) were secondary endpoints and are presented in outcome measure 23.
| percentage difference | BNT162-17 Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) - C4591001 BNT162b2 30 μg |
|---|---|
| Part B - Difference in SR to B.1.617.2 NT 1 Month After 1 Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From C4591001 (NCT04368728) | -2.39 (-7.74 to 2.84) |
Seroresponse was defined as a ≥4-fold rise in neutralizing titer from baseline. For subjects with a baseline titer less than the lower limit of quantitation (\<LLOQ), seroresponse was defined as a post-vaccination titer of ≥4× LLOQ. Adjusted difference was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. Associated 2-sided 95% CI based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in seroresponse data are presented below as per the primary endpoint defined in the protocol. Seroresponses for the individual arms (from which the difference was derived) were secondary endpoints and are presented in outcome measure 25.
| percentage difference | BNT162-17 Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) / C4591001 BNT162b2 30 μg |
|---|---|
| Part B - Difference in SR to B.1.617.2 NT 1 Month After 1 Dose of BNT162b2 (B.1.617.2) in BNT162b2-experienced Participants to the Reference Strain NT 1 Month After 2 Doses of BNT162b2 in Participants From C4591001 (NCT04368728) | 9.70 (5.68 to 13.97) |
Cohort B6 aimed to generate data to support a 2-dose primary regimen of alpha-delta multivalent BNT162b2 vaccine in SARS-CoV-2 naïve, unvaccinated individuals. The population recruited in Cohort B6, while complying with the inclusion criterium of no known history SARS-CoV-2 infection, were retrospectively seropositive for SARS-CoV-2 by planned N-binding antibody assessment of baseline samples. While the cohort was COVID-19 vaccine-naïve, it was not SARS-CoV-2-naïve as needed to match the control group (C4591001/NCT04368728). Procedurally, submission of a protocol amendment was not possible. However, the Statistical Analysis Plan was amended to describe that the non-inferiority analysis could not be performed according to the protocol. Control participants were not selected as planned; therefore, data were not available to calculate the GMR. Available GMT data for the 17 Cohort B6 participants without evidence of infection were analyzed and are presented in Outcome Measure 28.
No measurements were reported for this outcome.
Cohort B6 aimed to generate data to support a 2-dose primary regimen of alpha-delta multivalent BNT162b2 vaccine in SARS-CoV-2 naïve, unvaccinated individuals. The population recruited in Cohort B6, while complying with the inclusion criterium of no known history SARS-CoV-2 infection, were retrospectively seropositive for SARS-CoV-2 by planned N-binding antibody assessment of baseline samples. While the cohort was COVID-19 vaccine-naïve, it was not SARS-CoV-2-naïve as needed to match the control group (C4591001/NCT04368728). Procedurally, submission of a protocol amendment was not possible. However, the Statistical Analysis Plan was amended to describe that the non-inferiority analysis could not be performed according to the protocol. Control participants were not selected as planned; therefore, data were not available to calculate the GMR. Available GMT data for the 17 Part B Cohort 6 participants without evidence of infection were analyzed and are presented in Outcome Measure 28.
No measurements were reported for this outcome.
Cohort B6 aimed to generate data to support a 2-dose primary regimen of alpha-delta multivalent BNT162b2 vaccine in SARS-CoV-2 naïve, unvaccinated individuals. The population recruited in Cohort B6, while complying with the inclusion criterium of no known history SARS-CoV-2 infection, were retrospectively seropositive for SARS-CoV-2 by planned N-binding antibody assessment of baseline samples. While the cohort was COVID-19 vaccine-naïve, it was not SARS-CoV-2-naïve as needed to match the control group (C4591001/NCT04368728). Procedurally, submission of a protocol amendment was not possible. However, the Statistical Analysis Plan was amended to describe that non-inferiority analysis could not be performed according to the protocol. Control participants were not selected as planned; therefore, data were not available to calculate difference in SR. Available SR data for the 17 Part B Cohort 6 participants without evidence of infection were analyzed and presented in Outcome Measure 31.
No measurements were reported for this outcome.
Cohort B6 aimed to generate data to support a 2-dose primary regimen of alpha-delta multivalent BNT162b2 vaccine in SARS-CoV-2 naïve, unvaccinated individuals. The population recruited in Cohort B6, while complying with the inclusion criterium of no known history SARS-CoV-2 infection, were retrospectively seropositive for SARS-CoV-2 by planned N-binding antibody assessment of baseline samples. While the cohort was COVID-19 vaccine-naïve, it was not SARS-CoV-2-naïve as needed to match the control group (C4591001/NCT04368728). Procedurally, submission of a protocol amendment was not possible. However, the Statistical Analysis Plan was amended to describe that the non-inferiority analysis could not be performed according to the protocol. Control participants were not selected as planned; therefore data were not available to calculate difference in SR. Available SR data for the 17 Part B Cohort 6 participants without evidence of infection were analyzed and presented in Outcome Measure 31.
No measurements were reported for this outcome.
GMR of reference strain NT 3 weeks (3W) after one dose (PD1) of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection to the reference strain NT 1 month after two doses of BNT162b2 in participants without evidence of infection (COVID-19 Vaccine-naïve Participants) from the Phase III trial C4591001 (NCT04368728). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and corresponding CIs (based on the Student t distribution). Assay results below LLOQ were set to 0.5 × LLOQ. GMTs of NTs are presented in the descriptive data section of this outcome measure. GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of LS means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. GMR data are presented in the statistical analysis section.
| Titer | BNT162-17 - C6: 3 Doses 30μg BNT162b2 (B.1.1.7+B.1.617.2) With Evidence of Prior Infection 3W PD1 | C4591001 BNT162b2 30 μg Without Evidence of Infection - 1 Month Post-Dose 2 |
|---|---|---|
| Part B - GMR of Reference Strain NT After One Dose of BNT162b2 (B.1.1.7 + B.1.617.2) in Participants With Evidence of Prior Infection to the Reference Strain NT After 2 Doses of BNT162b2 in Participants Without Evidence of Infection | 17404.2 (15485.1 to 19561.1) | 1328.1 (1183.1 to 1491.0) |
The difference in SRs to the reference strain NT 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection to the reference strain NT 1 month after two doses of BNT162b2 in participants without evidence of infection from the Phase III trial C4591001 (NCT04368728). SR was defined as achieving a ≥4-fold rise from baseline. If the baseline measurement was below the LLOQ, a post-vaccination assay result ≥4 × LLOQ was considered a SR. SR to the reference strain NTs are presented in the descriptive data section of this outcome measure. Adjusted difference in proportions was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. 2-Sided CI was based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in SR data are presented in the statistical analysis section.
| percentage of participants | BNT162-17 - C6: 3 Doses 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) With Evidence of Prior Infection 3W PD1 | C4591001 BNT162b2 30 μg Without Evidence of Infection - 1 Month Post-Dose 2 |
|---|---|---|
| Part B - The Difference in SRs to the Reference Strain NT in Subjects With Evidence of Prior Infection and to the Reference Strain NT in Participants Without Evidence of Infection (COVID-19 Vaccine-naïve Participants) | 85.8 (80.9 to 89.8) | 90.5 (86.5 to 93.7) |
GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of least square means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age and number of prior doses. The overall number of participants analyzed represents the number of participants with valid and determinate assay results for B.1.1.529.1 at the given dose/sampling time point within the specified window. GMR data are presented below as per the primary endpoint defined in the protocol. GMTs for the individual arms (from which the difference was derived) were secondary endpoints and are presented in outcome measure 32.
| Titer ratio | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 / Cohort 8: 1 Dose of 30 μg BNT162b2 |
|---|---|
| Part C - GMR of B.1.1.529.1 NT 1 Month After One Dose of BNT162b2 (B.1.1.529.1) in RNA-based COVID-19 Vaccine-experienced Participants With History of SARS-CoV-2 Infection to Those at 1 Month After One Dose of BNT162b2 for Cohorts 7 and 8. | 0.94 (0.61 to 1.44) |
SR was defined as a ≥4-fold rise in neutralizing titer from baseline. For participants with a baseline titer less than the lower limit of quantitation (\<LLOQ), SR was defined as a post-vaccination titer of ≥4× LLOQ. SR to the reference strain NTs are presented in the descriptive data section of this outcome measure. Adjusted difference was estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. Associated 2-sided 95% CI were based on the Newcombe method with minimum risk weights for the difference in proportions. Difference in SR data are presented in the statistical analysis section.
| percentage of participants | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 Original Vaccine |
|---|---|---|
| Part C - The Difference in SR of B.1.1.529.1 NT 1 Month After One Dose of BNT162b2 (B.1.1.529.1) in RNA-based COVID-19 Vaccine-experienced Participants With History of SARS-CoV-2 Infection to Those at 1 Month After One Dose of BNT162b2 for Cohorts 7 & 8. | 59.4 (46.4 to 71.5) | 22.8 (12.7 to 35.8) |
For BNT162b2-experienced participants (defined as participants who have previously received two injections of 30 μg BNT162b2). Reference and variant(s) of concern (VOC) specific NT. GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ. Cohorts 1, 3, 4 and 5 received only 1 dose of IMP. Cohort 2 received dose 2 on Day 56 and did not receive dose 3. Cohort 6 received dose 2 on Day 21 and received dose 3 approximately 6 months after dose 2.
| Titer | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Orginal Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) |
|---|---|---|---|---|---|---|
| Pre IMP dose 1 - B.1.1.7 | 18.9 (9.0 to 39.7) | 26.9 (14.5 to 49.9) | 17.4 (9.0 to 33.8) | 48.4 (20.0 to 117.0) | 9.6 (5.2 to 17.8) | 6.9 (4.6 to 10.5) |
| 1-week post IMP dose 1 - B.1.1.7 | 1403.9 (817.9 to 2409.8) | 1340.5 (731.0 to 2458.2) | 1090.8 (701.7 to 1695.5) | 557.2 (365.4 to 849.4) | 307.9 (209.1 to 453.5) | 30.2 (6.8 to 133.1) |
| 3-weeks post IMP dose 1 - B.1.1.7 | 1035.7 (659.9 to 1625.5) | 1168.4 (756.8 to 1803.9) | 956.0 (657.3 to 1390.4) | 493.5 (365.0 to 667.3) | 361.6 (223.9 to 584.2) | — |
| 1-month post IMP dose 1 - B.1.1.7 | 942.8 (552.6 to 1608.3) | 1004.3 (705.3 to 1430.0) | 1009.8 (697.8 to 1461.3) | 468.5 (308.6 to 711.2) | 314.5 (182.7 to 541.3) | — |
| 6-months post IMP dose 1 - B.1.1.7 | 156.6 (62.5 to 392.2) | — | 352.3 (192.4 to 645.3) | 151.5 (68.9 to 333.1) | 85.7 (36.9 to 199.3) | — |
| 12-months post IMP dose 1 - B.1.1.7 | 658.8 (385.8 to 1124.7) | — | 463.9 (180.0 to 1195.5) | 241.0 (95.1 to 611.0) | 463.9 (188.0 to 1144.8) | — |
| Pre IMP dose 2 - B.1.1.7 | — | 151 (49.1 to 464.5) | — | — | — | 42.7 (12.5 to 145.9) |
| 1-week post IMP dose 2 - B.1.1.7 | — | 987.0 (495.9 to 1964.4) | — | — | — | 207.5 (104.3 to 413.0) |
| 1-month post IMP dose 2 - B.1.1.7 | — | 958.9 (586.3 to 1568.3) | — | — | — | 216.1 (101.7 to 459.0) |
| 6-months post IMP dose 2 - B.1.1.7 | — | 349.0 (166.5 to 731.6) | — | — | — | — |
| 12-months post IMP dose 2 - B.1.1.7 | — | 940.6 (480.4 to 1841.7) | — | — | — | — |
| 6-months post IMP dose 2 + pre IMP dose 3 - B.1.1.7 | — | — | — | — | — | 68.3 (21.7 to 215.2) |
| 1-week post IMP dose 3 - B.1.1.7 | — | — | — | — | — | 640.0 (379.2 to 1080.2) |
| 1-month post IMP dose 3 - B.1.1.7 | — | — | — | — | — | 562.0 (190.2 to 1660.6) |
| 12-months post IMP dose 2 + 6-months post IMP dose 3 - B1.1.7 | — | — | — | — | — | 351.7 (162.4 to 761.8) |
| Pre IMP dose 1 - B.1.617.2 | 9.0 (4.8 to 16.7) | 8.7 (5.1 to 15.0) | 12.1 (6.4 to 22.8) | 8.7 (6.0 to 12.6) | 9.0 (5.2 to 15.8) | 6.5 (4.7 to 9.0) |
| 1-week post IMP dose 1 - B.1.617.2 | 526.6 (305.8 to 906.9) | 385.0 (255.6 to 579.8) | 517.1 (330.1 to 809.9) | 359.2 (237.3 to 543.7) | 254.0 (162.5 to 396.9) | 27.7 (6.6 to 115.4) |
| 3-weeks post IMP dose 1 - B.1.617.2 | 452.5 (283.1 to 723.5) | 384.0 (251.0 to 587.6) | 533.3 (368.0 to 772.7) | 380.5 (265.8 to 544.8) | 221.7 (123.0 to 399.6) | — |
| 1-month post IMP dose 1 - B.1.617.2 | 369.1 (209.3 to 650.8) | 303.8 (199.2 to 463.2) | 486.8 (349.2 to 678.6) | 288.4 (199.5 to 417.0) | 207.5 (126.3 to 340.8) | — |
| 6-months post IMP dose 1 - B.1.617.2 | 137.5 (51.6 to 366.1) | — | 217.7 (127.9 to 370.5) | 123.9 (55.3 to 277.7) | 35.6 (17.5 to 72.7) | — |
| 12-months post IMP dose 1 - B.1.617.2 | 640.0 (293.4 to 1396.1) | — | 199.9 (87.3 to 458.1) | 212.5 (78.3 to 576.2) | 226.3 (92.5 to 553.7) | — |
| Pre IMP dose 2 - B.1.617.2 | — | 235.2 (144.0 to 384.1) | — | — | — | 60.4 (18.3 to 199.5) |
| 1-week post IMP dose 2 - B.1.617.2 | — | 515.4 (342.7 to 774.9) | — | — | — | 216.7 (134.6 to 348.7) |
| 1-month post IMP dose 2 - B.1.617.2 | — | 517.8 (366.6 to 731.5) | — | — | — | 320.0 (139.1 to 736.4) |
| 6-months post IMP dose 2 - B.1.617.2 | — | 226.3 (114.9 to 445.6) | — | — | — | — |
| 12-months post IMP dose 2 - B.1.617.2 | — | 508.0 (288.7 to 893.9) | — | — | — | — |
| 6-months post IMP dose 2 + pre IMP dose 3 - B.1.617.2 | — | — | — | — | — | 87.9 (26.2 to 294.9) |
| 1-week post IMP dose 3 - B.1.617.2 | — | — | — | — | — | 819.8 (353.1 to 1903.2) |
| 1-month post IMP dose 3 - B.1.617.2 | — | — | — | — | — | 640.0 (207.3 to 1976.3) |
| 12-months post dose 2 + 6-months post dose 3 - B.1.617.2 | — | — | — | — | — | 424.9 (213.3 to 846.5) |
| Pre IMP dose 1 - Reference strain | 14.9 (8.5 to 26.2) | 18.7 (10.4 to 33.4) | 18.3 (10.1 to 33.3) | 27.8 (16.6 to 46.5) | 14.1 (7.9 to 25.3) | 6.8 (4.6 to 9.9) |
| 1-week post IMP dose 1 - Reference strain | 812.2 (474.1 to 1391.3) | 519.8 (321.6 to 840.2) | 640.0 (417.4 to 981.4) | 702.0 (432.7 to 1138.7) | 352.3 (238.3 to 521.0) | 25.4 (6.6 to 97.7) |
| 3-weeks post IMP dose 1 - Reference strain | 678.1 (406.0 to 1132.3) | 584.2 (357.5 to 954.8) | 740.6 (495.0 to 1107.8) | 748.0 (500.2 to 1118.6) | 408.7 (262.0 to 637.4) | — |
| 1-month post IMP dose 1 - Reference strain | 589.9 (376.9 to 923.1) | 452.5 (283.5 to 722.4) | 688.4 (467.0 to 1014.9) | 748.0 (469.3 to 1192.3) | 380.5 (232.0 to 624.3) | — |
| 6-months post IMP dose 1 - Reference strain | 163.5 (72.7 to 367.7) | — | 244.4 (143.8 to 415.4) | 101.4 (57.8 to 178.0) | 78.2 (42.2 to 145.0) | — |
| 12-months post IMP dose 1 - Reference strain | 604.1 (311.3 to 1172.1) | — | 380.5 (164.8 to 878.9) | 170.4 (67.6 to 429.5) | 565.5 (244.1 to 1310.2) | — |
| Pre IMP dose 2 - Reference strain | — | 387.9 (227.7 to 660.9) | — | — | — | 37.5 (11.3 to 124.6) |
| 1-week post IMP dose 2 - Reference strain | — | 697.9 (453.5 to 1074.1) | — | — | — | 95.1 (59.8 to 151.4) |
| 1-month post IMP dose 2 - Reference strain | — | 665.1 (400.1 to 1105.6) | — | — | — | 136.1 (58.1 to 319.0) |
| 6-months post IMP dose 2 - Reference strain | — | 334.2 (171.5 to 651.2) | — | — | — | — |
| 12-months post IMP dose 2 - Reference strain | — | 527.9 (263.8 to 1056.2) | — | — | — | — |
| 6-months post IMP dose 2 + pre IMP dose 3 - Reference strain | — | — | — | — | — | 53.1 (16.4 to 172.4) |
| 1-week post IMP dose 3 - Reference strain | — | — | — | — | — | 551.7 (299.8 to 1015.1) |
| 1-month post IMP dose 3 - Reference strain | — | — | — | — | — | 493.5 (195.5 to 1245.8) |
| 12-months post dose 2 + 6-months post dose 3 - Reference strain | — | — | — | — | — | 205.9 (80.1 to 528.8) |
For BNT162b2-experienced participants (defined as participants who have previously received two injections of 30 μg BNT162b2). Reference and VOC specific NT. GMFR is calculated as the mean of the difference of logarithmically transformed neutralization titers or antibody levels (later result minus earlier result) and exponentiating the mean. The associated 2-sided 95% CIs are obtained by constructing CIs using Student's t-distribution for the mean difference on the natural log scale and exponentiating the confidence limits. Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ. Cohorts 1, 3, 4 and 5 received only 1 dose of IMP. Cohort 2 received dose 2 on Day 56 and did not receive dose 3. Cohort 6 received dose 2 on Day 21 and received dose 3 approximately 6 months after dose 2.
| Fold rise | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Orginal Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) |
|---|---|---|---|---|---|---|
| 1-week post IMP dose 1 - B.1.1.7 | 68.6 (30.4 to 155.0) | 78.8 (38.9 to 159.7) | 95.5 (72.0 to 126.5) | 13.0 (5.8 to 28.9) | 31.4 (19.1 to 51.4) | 4.8 (1.2 to 18.9) |
| 3-weeks post IMP dose 1 - B.1.1.7 | 52.8 (28.4 to 98.2) | 39.8 (23.3 to 68.0) | 51.4 (30.3 to 87.3) | 10.2 (4.8 to 21.9) | 35.7 (20.6 to 61.6) | — |
| 1-month post IMP dose 1 - B.1.1.7 | 48.1 (24.8 to 93.2) | 37.4 (22.8 to 61.4) | 54.3 (31.9 to 92.5) | 9.7 (3.8 to 24.8) | 27.7 (14.0 to 55.2) | — |
| 6-months post IMP dose 1 - B.1.1.7 | 7.2 (2.9 to 18.0) | — | 18.7 (8.2 to 42.5) | 2.9 (0.9 to 9.6) | 9.0 (3.7 to 22.0) | — |
| 12-months post IMP dose 1 - B.1.1.7 | 21.1 (4.6 to 96.4) | — | 20.5 (6.2 to 68.2) | 4.0 (0.5 to 33.3) | 36.3 (13.8 to 95.5) | — |
| Pre IMP dose 2 - B.1.1.7 | — | 6.2 (2.4 to 15.9) | — | — | — | 6.2 (2.2 to 17.4) |
| 1-week post IMP dose 2 - B.1.1.7 | — | 64.0 (37.4 to 109.4) | — | — | — | 41.5 (20.9 to 82.6) |
| 1-month post IMP dose 2 - B.1.1.7 | — | 39.5 (22.2 to 70.6) | — | — | — | 33.6 (17.9 to 63.3) |
| 6-months post IMP dose 2 - B.1.1.7 | — | 15.7 (7.4 to 33.2) | — | — | — | — |
| 12-months post IMP dose 2 - B.1.1.7 | — | 22.6 (6.7 to 76.7) | — | — | — | — |
| 6-months post IMP dose 2 + pre IMP dose 3 - B.1.1.7 | — | — | — | — | — | 12.4 (4.3 to 35.8) |
| 1-week post IMP dose 3 - B.1.1.7 | — | — | — | — | — | 105.0 (76.8 to 143.6) |
| 1-month post IMP dose 3 - B.1.1.7 | — | — | — | — | — | 82.0 (32.1 to 209.5) |
| 12-months post dose 2 + 6-months post dose 3 - B.1.1.7 | — | — | — | — | — | 53.8 (25.6 to 113.0) |
| 1-week post IMP dose 1 - B.1.617.2 | 52.7 (28.1 to 98.8) | 64.0 (43.6 to 93.9) | 73.1 (51.1 to 104.6) | 35.9 (21.7 to 59.6) | 27.2 (16.3 to 45.4) | 4.9 (1.2 to 19.5) |
| 3-weeks post IMP dose 1 - B.1.617.2 | 48.9 (28.4 to 84.2) | 42.8 (27.6 to 66.5) | 42.1 (26.2 to 67.6) | 43.7 (27.1 to 70.6) | 22.6 (12.3 to 41.7) | — |
| 1-month post IMP dose 1 - B.1.617.2 | 40.9 (23.4 to 71.5) | 34.9 (23.5 to 51.7) | 38.4 (22.1 to 66.7) | 33.1 (22.4 to 49.1) | 20.0 (11.7 to 34.2) | — |
| 6-months post IMP dose 1 - B.1.617.2 | 13.8 (5.3 to 35.6) | — | 16.3 (8.1 to 32.9) | 14.3 (5.8 to 35.4) | 4.4 (1.9 to 9.9) | — |
| 12-months post IMP dose 1 - B.1.617.2 | 42.2 (10.5 to 169.8) | — | 12.8 (4.4 to 37.4) | 21.9 (5.2 to 93.3) | 19.3 (6.9 to 54.0) | — |
| Pre IMP dose 2 - B.1.617.2 | — | 27.4 (16.8 to 44.7) | — | — | — | 9.3 (3.2 to 27.5) |
| 1-week post IMP dose 2 - B.1.617.2 | — | 86.7 (53.9 to 139.5) | — | — | — | 43.3 (26.9 to 69.7) |
| 1-month post IMP dose 2 - B.1.617.2 | — | 60.4 (32.9 to 110.8) | — | — | — | 55.2 (24.0 to 126.9) |
| 6-months post IMP dose 2 - B.1.617.2 | — | 26.9 (11.7 to 62.0) | — | — | — | — |
| 12-months post IMP dose 2 - B.1.617.2 | — | 34.6 (8.1 to 146.7) | — | — | — | — |
| 6-months post IMP dose 2 + pre IMP dose 3 - B.1.617.2 | — | — | — | — | — | 16.5 (5.0 to 54.5) |
| 1-week post IMP dose 3 - B.1.617.2 | — | — | — | — | — | 121.8 (63.4 to 233.9) |
| 1-month post IMP dose 3 - B.1.617.2 | — | — | — | — | — | 86.1 (28.2 to 263.2) |
| 12-months post dose 2 + 6-months post dose 3 - B.1.617.2 | — | — | — | — | — | 61.8 (30.8 to 124.0) |
| 1-week post IMP dose 1 - Reference strain | 52.7 (33.3 to 83.2) | 39.4 (21.6 to 71.9) | 50.3 (38.7 to 65.4) | 20.6 (11.0 to 38.7) | 23.1 (15.8 to 33.8) | 4.1 (1.3 to 13.3) |
| 3-weeks post IMP dose 1 - Reference strain | 46.1 (28.1 to 75.8) | 29.2 (18.3 to 46.7) | 37.7 (22.0 to 64.8) | 26.9 (15.6 to 46.3) | 26.3 (16.5 to 42.0) | — |
| 1-month post IMP dose 1 - Reference strain | 40.9 (26.8 to 62.3) | 24.3 (15.0 to 39.1) | 36.4 (20.8 to 63.7) | 26.9 (15.9 to 45.6) | 23.1 (14.7 to 36.3) | — |
| 6-months post IMP dose 1 - Reference strain | 10.5 (5.1 to 21.5) | — | 12.5 (6.1 to 25.4) | 3.7 (1.8 to 7.5) | 5.2 (2.9 to 9.2) | — |
| 12-months post IMP dose 1 - Reference strain | 29.9 (9.2 to 97.1) | — | 17.7 (6.6 to 47.4) | 6.0 (1.4 to 25.1) | 26.5 (11.1 to 63.4) | — |
| Pre IMP dose 2 - Reference strain | — | 21.8 (12.8 to 37.2) | — | — | — | 5.5 (2.0 to 15.1) |
| 1-week post IMP dose 2 - Reference strain | — | 66.8 (27.7 to 161.5) | — | — | — | 19.0 (12.0 to 30.3) |
| 1-month post IMP dose 2 - Reference strain | — | 37.3 (21.6 to 64.6) | — | — | — | 21.5 (10.5 to 44.2) |
| 6-months post IMP dose 2 - Reference strain | — | 18.6 (9.1 to 38.0) | — | — | — | — |
| 12-months post IMP dose 2 - Reference strain | — | 21.0 (5.3 to 83.5) | — | — | — | — |
| 6-months post IMP dose 2 + pre IMP dose 3 - Reference strain | — | — | — | — | — | 10.0 (3.3 to 30.2) |
| 1-week post IMP dose 3 - Reference strain | — | — | — | — | — | 82.0 (52.7 to 127.6) |
| 1-month post IMP dose 3 - Reference strain | — | — | — | — | — | 74.2 (34.7 to 158.7) |
| 12-months post dose 2 + 6-months post dose 3 - Reference strain | — | — | — | — | — | 32.0 (10.8 to 95.2) |
For BNT162b2-experienced participants (defined as participants who have previously received two injections of 30 μg BNT162b2). Reference and VOC specific NT. SR is defined as a ≥4-fold rise in neutralizing titer from baseline (pre IMP dose 1). For subjects with a baseline titer less than the LLOQ, SR is defined as a post-vaccination titer of ≥4 × LLOQ. Pre IMP dose 2 is also 2 months post dose 1 for Cohort 2 and 3 weeks post dose 1 for Cohort 6. Cohorts 1, 3, 4 and 5 received only 1 dose of IMP. Cohort 2 received dose 2 on Day 56 and did not receive dose 3. Cohort 6 received dose 2 on Day 21 and received dose 3 approximately 6 months after dose 2.
| Percentage of participants | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Orginal Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) |
|---|---|---|---|---|---|---|
| 1-week post IMP dose 1 - B.1.1.7 | 93.3 | 100 | 100 | 66.7 | 94.1 | 33.3 |
| 3-weeks post IMP dose 1 - B.1.1.7 | 94.4 | 94.7 | 94.7 | 65.0 | 100.0 | — |
| 1-month post IMP dose 1 - B.1.1.7 | 94.1 | 95.0 | 100 | 65.0 | 88.2 | — |
| 6-months post IMP dose 1 - B.1.1.7 | 64.3 | — | 83.3 | 47.4 | 75.0 | — |
| 12-months post IMP dose 1 - B.1.1.7 | 80.0 | — | 64.3 | 54.5 | 90.9 | — |
| Pre IMP dose 2 - B.1.1.7 | — | 61.1 | — | — | — | 43.8 |
| 1-week post IMP dose 2 - B.1.1.7 | — | 100 | — | — | — | 100.0 |
| 1-month post IMP dose 2 - B.1.1.7 | — | 94.4 | — | — | — | 92.9 |
| 6-months post IMP dose 2 + pre IMP dose 3 - B.1.1.7 | — | — | — | — | — | 63.6 |
| 1-week post IMP dose 3 - B.1.1.7 | — | — | — | — | — | 100.0 |
| 1-month post IMP dose 3 - B.1.1.7 | — | — | — | — | — | 100.0 |
| 6-months post IMP dose 2 - B.1.1.7 | — | 87.5 | — | — | — | — |
| 12-months post dose 2 + 6-months post dose 3 - B.1.1.7 | — | — | — | — | — | 100.0 |
| 12-months post IMP dose 2 - B.1.1.7 | — | 88.9 | — | — | — | — |
| 1-week post IMP dose 1 - B.1.617.2 | 93.8 | 100.0 | 100.0 | 100.0 | 88.2 | 33.3 |
| 3-weeks post IMP dose 1 - B.1.617.2 | 94.4 | 94.7 | 100.0 | 100.0 | 93.8 | — |
| 1-month post IMP dose 1 - B.1.617.2 | 100.0 | 95.0 | 94.7 | 100.0 | 88.2 | — |
| 6-months post IMP dose 1 - B.1.617.2 | 78.6 | — | 88.9 | 73.7 | 58.3 | — |
| 12-months post IMP dose 1 - B.1.617.2 | 90.0 | — | 57.1 | 81.8 | 81.8 | — |
| Pre IMP dose 2 - B.1.617.2 | — | 94.4 | — | — | — | 56.3 |
| 1-week post IMP dose 2 - B.1.617.2 | — | 100 | — | — | — | 100 |
| 1-month post IMP dose 2 - B.1.617.2 | — | 94.4 | — | — | — | 92.9 |
| 6-months post IMP dose 2 + pre IMP dose 3 - B.1.617.2 | — | — | — | — | — | 72.7 |
| 1-week post IMP dose 3 - B.1.617.2 | — | — | — | — | — | 100.0 |
| 1-month post IMP dose 3 - B.1.617.2 | — | — | — | — | — | 100.0 |
| 6-months post IMP dose 2 - B.1.617.2 | — | 81.3 | — | — | — | — |
| 12-months post dose 2 + 6-months post dose 3 - B.1.617.2 | — | — | — | — | — | 100 |
| 12-months post IMP dose 2 - B.1.617.2 | — | 88.9 | — | — | — | — |
| 1-week post IMP dose 1 - Reference strain | 100 | 100.0 | 100.0 | 86.7 | 94.1 | 33.3 |
| 3-weeks post IMP dose 1 - Reference strain | 100 | 100.0 | 94.7 | 95.0 | 100.0 | — |
| 1-month post IMP dose 1 - Reference strain | 100 | 95.0 | 94.7 | 95.0 | 100.0 | — |
| 6-months post IMP dose 1 - Reference strain | 64.3 | — | 83.3 | 36.8 | 58.3 | — |
| 12-months post IMP dose 1 - Reference strain | 90.0 | — | 85.7 | 54.5 | 90.9 | — |
| Pre IMP dose 2 - Reference strain | — | 94.4 | — | — | — | 43.8 |
| 1-week post IMP dose 2 - Reference strain | — | 100.0 | — | — | — | 100.0 |
| 1-month post IMP dose 2 - Reference strain | — | 100.0 | — | — | — | 85.7 |
| 6-months post IMP dose 2 + pre IMP dose 3 - Reference strain | — | — | — | — | — | 54.5 |
| 1-week post IMP dose 3 - Reference strain | — | — | — | — | — | 100.0 |
| 1-month post IMP dose 3 - Reference strain | — | — | — | — | — | 100.0 |
| 6-months post IMP dose 2 - Reference strain | — | 93.8 | — | — | — | — |
| 12-months post dose 2 + 6-months post dose 3 - Reference strain | — | — | — | — | — | 100.0 |
| 12-months post IMP dose 2 - Reference strain | — | 88.9 | — | — | — | — |
GMTs of VOCs (B.1.1.7 and B.1.617.2) and reference strain 1 month after 1 dose of BNT162 (B.1.1.7+B.1.167.2) in participants from Part B Cohort 1 of the BNT162-17 trial (BNT162b2-experienced participants), and reference strain 1 month after 2 doses of BNT162b2 in selected participants from the Phase III C4591001 (NCT04368728) trial. GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ.
| Titer | BNT162-17 Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | C4591001 BNT162b2 30 μg |
|---|---|---|
| B.1.1.7 | 996.5 (880.3 to 1128.0) | 74.7 (66.1 to 84.3) |
| B.1.617.2 | 552.4 (495.2 to 616.2) | 65.2 (57.5 to 74.0) |
| Reference strain | 947.0 (846.4 to 1059.5) | 113.3 (101.4 to 126.5) |
Percentage of participants achieving SR at 1 month after 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants (Cohort 1) and 1 month after 2 doses of BNT162b2 primary series (participants from C4591001 \[NCT04368728\]). SR is defined as a ≥4-fold rise in neutralizing titer from baseline (pre IMP dose 1). For participants with a baseline titer less than the LLOQ, SR is defined as a post-vaccination titer of ≥4 × LLOQ.
| Percentage of participants | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | C4591001 BNT162b2 30 μg |
|---|---|---|
| B.1.1.7 | 88.6 (84.4 to 92.0) | 76.2 (71.3 to 80.7) |
| B.1.617.2 | 85.9 (81.4 to 89.6) | 74.4 (69.3 to 79.0) |
| Reference strain | 89.6 (85.6 to 92.8) | 88.3 (84.3 to 91.5) |
GMTs of VOCs (B.1.617.2) and reference strain 1 month after 1 dose of BNT162 (B.1.167.2) in participants from Part B Cohort 4 of the BNT162-17 trial (BNT162b2-experienced participants), and 1 month after 2 doses of BNT162b2 in selected participants from the Phase III C4591001 (NCT04368728) trial. GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ.
| Titer | Part B - Cohort 4 - 1 Dose 30 μg BNT162b2 (B.1.617.2) | C4591001 BNT162b2 30 μg |
|---|---|---|
| B.1.1.7 | 972.8 (875.3 to 1081.1) | 78.6 (69.6 to 88.8) |
| B.1.617.2 | 730.5 (654.5 to 815.3) | 71.2 (62.7 to 80.8) |
| Reference strain | 1005.3 (900.3 to 1122.5) | 113.0 (100.5 to 127.1) |
Percentage of participants achieving SR at 1 month after 1 dose of BNT162b2 (B.1.617.2) in BNT162b2-experienced subjects (Part B - Cohort 4) and 1 month after 2 doses of BNT162b2 primary series (participants from C4591001 \[NCT04368728\]). SR is defined as a ≥4-fold rise in neutralizing titer from baseline (pre IMP dose 1). For participants with a baseline titer less than the LLOQ, SR is defined as a post-vaccination titer of ≥4 × LLOQ.
| Percentage of participants | Part B - Cohort 4 - 1 Dose 30 μg BNT162b2 (B.1.617.2) | C4591001 BNT162b2 30 μg |
|---|---|---|
| B.1.1.7 | 96.5 (93.8 to 98.2) | 78.4 (73.5 to 82.8) |
| B.1.617.2 | 97.4 (95.0 to 98.9) | 77.5 (72.5 to 82.0) |
| Reference strain | 98.1 (95.9 to 99.3) | 87.5 (83.4 to 90.9) |
GMTs of VOCs and reference strain NT 1 month after dose 2 and dose 3 of BNT162b2 (B.1.1.7 + B.1.617.2) (Part B - Cohort 6). GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ.
| Titer | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.6172) |
|---|---|
| 1 month post IMP dose 2 - B.1.1.7 | 832.5 (718.2 to 965.0) |
| 1 month post IMP dose 3 - B.1.1.7 | 942.6 (836.4 to 1062.4) |
| 1 month post IMP dose 2 - B.1.617.2 | 1184.6 (1015.5 to 1381.9) |
| 1 month post IMP dose 3 - B.1.617.2 | 1270.9 (1130.2 to 1429.0) |
| 1 month post IMP dose 2 - Reference strain | 697.5 (594.0 to 819.1) |
| 1 month post IMP dose 3 - Reference strain | 830.5 (736.3 to 936.8) |
Percentage of participants achieving SR to VOCs (B.1.1.7, B.1.617.2) and reference strain at 1 month after dose 2 and dose 3 of BNT162b2 (B.1.1.7 + B.1.617.2) (Part B - Cohort 6). SR is defined as a ≥4-fold rise in neutralizing titer from baseline (pre IMP dose 1). For participants with a baseline titer less than the LLOQ, SR is defined as a post vaccination titer of ≥4 × LLOQ. Pre IMP dose 2 is also 3 weeks post dose 1 for Cohort 6.
| Percentage of participants | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.6172) |
|---|---|
| 1 month post IMP dose 2 - B.1.1.7 | 86.8 (82.2 to 90.5) |
| 1 month post IMP dose 3 - B.1.1.7 | 83.6 (78.8 to 87.7) |
| 1 month post IMP dose 2 - B.1.617.2 | 88.9 (84.7 to 92.4) |
| 1 month post IMP dose 3 - B.1.617.2 | 87.1 (82.7 to 90.8) |
| 1 month post IMP dose 2 - Reference strain | 87.5 (83.0 to 91.1) |
| 1 month post IMP dose 3 - Reference strain | 89.5 (85.4 to 92.8) |
GMTs of VOC specific NTs (B.1.1.7, B.1.617.2, B.1.1.529.5 \[Omicron BA.5\]) 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection (Cohort 6), 1 month after two doses of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants without evidence of infection (Cohort 6), and 1 month after one booster dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants without evidence of infection (Cohort 1). GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ; assay results above the ULOQ were set to ULOQ.
| Titer | Part B - Cohort 6: BNT162b2 With Evidence of Prior Infection | Part B - Cohort 6: BNT162b2 Without Evidence of Infection | Part B - Cohort 1: BNT162b2 Without Evidence of Infection |
|---|---|---|---|
| SARS-CoV-2 neutralization assay - B.1.1.7 | 1045.3 (853.1 to 1280.8) | 180.8 (91.8 to 356.3) | 749.5 (621.1 to 904.6) |
| SARS-CoV-2 neutralization assay - B.1.617.2 | 859.9 (693.4 to 1066.4) | 62.6 (30.9 to 127.0) | 466.6 (401.8 to 541.9) |
| SARS-CoV-2 neutralization assay - B.1.1.529.5 | 229.3 (191.7 to 274.4) | 10.2 (5.7 to 18.3) | 80.8 (66.9 to 97.6) |
GMR of VOC specific NTs (B.1.1.7, B.1.617.2, B.1.1.529.5 \[Omicron BA.5\]) 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection (Cohort 6) to the VOCs NTs 1 month after two doses of BNT162b2 (B.1.1.7 + B.1.617.2) in participants without evidence of infection (Cohort 6), and to the VOCs NTs 1 month after one booster dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants without evidence of infection (Cohort 1). GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of the LS means and corresponding CIs based on the analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of age, sex, and group. A separate model was fit for each comparison. Assay results below the LLOQ were set to 0.5 × LLOQ; assay results above the ULOQ were set to ULOQ.
| Titer ratio | Part B - Cohort 6 With Prior Infection / Cohort 6 Without Prior Infection | Part B - Cohort 6 With Prior Infection / Cohort 1 Without Prior Infection |
|---|---|---|
| SARS-CoV-2 neutralization assay - B.1.1.7 | 7.66 (4.09 to 14.33) | 1.46 (1.10 to 1.93) |
| SARS-CoV-2 neutralization assay - B.1.617.2 | 15.43 (7.87 to 30.28) | 1.88 (1.44 to 2.45) |
| SARS-CoV-2 neutralization assay - B.1.1.529.5 | 29.86 (17.31 to 51.49) | 2.94 (2.26 to 3.82) |
The difference in SRs to VOC specific NTs (B.1.1.7, B.1.617.2, B.1.1.529.5 \[Omicron BA.5\]) 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection (Cohort 6) to those 1 month after two doses of BNT162b2 (B.1.1.7 + B.1.617.2) in participants without evidence of infection (Cohort 6), and to those 1 month after one booster dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants without evidence of infection (Cohort 1). Adjusted difference in proportions estimated using minimum risk weights and stratified by sex and age group (18 to 55 years, 56 to 85 years), expressed as a percentage. 2-Sided CI based on the Newcombe method stratified by sex and age group (18 to 55 years, 56 to 85 years) with minimum risk weights for the difference in proportions.
| Percentage difference | Part B - Cohort 6 With Prior Infection / Cohort 6 Without Prior Infection | Part B - Cohort 6 With Prior Infection / Cohort 1 Without Prior Infection |
|---|---|---|
| SARS-CoV-2 neutralization assay - B.1.1.7 | 6.95 (-9.69 to 32.17) | -9.75 (-16.43 to -3.24) |
| SARS-CoV-2 neutralization assay - B.1.617.2 | 20.90 (-0.62 to 46.52) | -6.56 (-13.03 to -0.37) |
| SARS-CoV-2 neutralization assay - B.1.1.529.5 | 81.47 (54.28 to 90.07) | 6.67 (-2.06 to 15.42) |
SRs of VOC specific NTs (B.1.1.7, B.1.617.2, B.1.1.529.5 \[Omicron BA.5\]) 3 weeks after one dose of BNT162b2 (B.1.1.7 + B.1.617.2) in COVID-19 vaccine-naïve participants with evidence of prior infection (Cohort 6) 1 month after two doses of BNT162b2 (B.1.1.7 + B.1.617.2) in participants without evidence of infection (Cohort 6), and 1 month after one booster dose of BNT162b2 (B.1.1.7 + B.1.617.2) in BNT162b2-experienced participants without evidence of infection (Cohort 1). Seroresponse was defined as achieving a ≥4-fold rise from baseline. If the baseline measurement was below the LLOQ, a postvaccination assay result ≥4 × LLOQ was considered a seroresponse.
| Percentage of participants | Part B - Cohort 6: BNT162b2 With Evidence of Prior Infection | Part B - Cohort 6: BNT162b2 Without Evidence of Infection | Part B - Cohort 1: BNT162b2 Without Evidence of Infection |
|---|---|---|---|
| SARS-CoV-2 neutralization assay - B.1.1.7 | 87.3 (80.7 to 92.3) | 76.5 (50.1 to 93.2) | 97.1 (92.6 to 99.2) |
| SARS-CoV-2 neutralization assay - B.1.617.2 | 89.4 (83.2 to 94.0) | 58.8 (32.9 to 81.6) | 96.3 (91.6 to 98.8) |
| SARS-CoV-2 neutralization assay - B.1.1.529.5 | 87.3 (80.7 to 92.3) | 11.8 (1.5 to 36.4) | 80.1 (72.4 to 86.5) |
VOC NT in RNA-based COVID-19 vaccine-experienced participants with history of SARS-CoV-2 infection at baseline and 7 days, 1 month, and 3 months after the trial start for Cohorts 7, 8, and 9, and 6 and 12 months after the trial start for Cohorts 7 and 8. GMTs and 2-sided 95% CIs are calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ are set to 0.5 × LLOQ and above the ULOQ are set to ULOQ. Number of subjects with valid and determinate assay results for the specified variant at the given dose/sampling time point. No vaccination was given to Cohort 9 participants within 3 months after Visit 1. The term "post IMP" does not apply for Cohort 9 since no IMP was given, but blood was collected at the same timepoints post randomization.
| Titer | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529.1) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination |
|---|---|---|---|
| Baseline | 169.2 (124.4 to 230.2) | 388.5 (262.0 to 575.9) | 164.0 (96.1 to 280.0) |
| 1-week post IMP Dose 1 | 751.7 (571.5 to 988.9) | 768.9 (550.0 to 1074.9) | 211.7 (122.5 to 365.9) |
| 1-month post IMP Dose 1 | 748.8 (572.0 to 980.3) | 801.5 (569.8 to 1127.4) | 180.4 (106.7 to 305.0) |
| 3-months post IMP Dose 1 | 590.3 (433.6 to 803.6) | 571.5 (411.5 to 793.8) | 143.3 (86.7 to 236.9) |
| 6-months post IMP Dose 1 | 289.6 (210.7 to 397.9) | 356.8 (266.9 to 476.8) | — |
| 12-months post IMP Dose 1 | 197.0 (142.5 to 272.3) | 180.5 (135.9 to 239.8) | — |
Collected over AEs: From Dose 1 to 1 Month after each dose; SAEs: From Dose 1 up to end of study, i.e., up to 18 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - Cohort 1: 1 Dose of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | 0/21 (0%) | 0/21 (0%) | 2/21 (9.5%) |
| Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | 0/20 (0%) | 1/20 (5%) | 7/20 (35%) |
| Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | 0/20 (0%) | 1/20 (5%) | 4/20 (20%) |
| Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | 0/42 (0%) | 0/42 (0%) | 27/42 (64.3%) |
| Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | 0/17 (0%) | 0/17 (0%) | 6/17 (35.3%) |
| Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | 1/349 (0.3%) | 6/349 (1.7%) | 26/349 (7.4%) |
| Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | 0/352 (0%) | 9/352 (2.6%) | 0/352 (0%) |
| Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | 2/361 (0.6%) | 13/361 (3.6%) | 39/361 (10.8%) |
| Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | 0/72 (0%) | 0/72 (0%) | 4/72 (5.6%) |
| Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | 0/71 (0%) | 5/71 (7%) | 5/71 (7%) |
| Event | Part A - Cohort 1: 1 Dose of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Obstructive pancreatitisGastrointestinal disorders | 0/21 | 0/20 | 1/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
| Hepatitis acuteHepatobiliary disorders | 0/21 | 1/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
| CholelithiasisHepatobiliary disorders | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 1/71 |
| Fibula fractureInjury, poisoning and procedural complications | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 1/71 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 1/71 |
| Tibia fractureInjury, poisoning and procedural complications | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 1/71 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 1/71 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 1/71 |
| EpilepsyNervous system disorders | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 1/71 |
| SeizureNervous system disorders | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 1/71 |
| Event | Part A - Cohort 1: 1 Dose of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product administration errorInjury, poisoning and procedural complications | 0/21 | 0/20 | 0/20 | 0/20 | 22/42 | 0/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
| FatigueGeneral disorders | 1/21 | 4/20 | 2/20 | 0/20 | 2/42 | 2/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
| HeadacheNervous system disorders | 1/21 | 1/20 | 1/20 | 0/20 | 1/42 | 3/17 | 0/349 | 0/352 | 0/361 | 0/72 | 4/71 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 2/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 2/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
| COVID-19Infections and infestations | 0/21 | 2/20 | 1/20 | 0/20 | 0/42 | 1/17 | 26/349 | 0/352 | 39/361 | 0/72 | 0/71 |
| LymphadenopathyBlood and lymphatic system disorders | 1/21 | 1/20 | 2/20 | 0/20 | 1/42 | 0/17 | 0/349 | 0/352 | 0/361 | 4/72 | 1/71 |
| DiarrhoeaGastrointestinal disorders | 0/21 | 2/20 | 0/20 | 0/20 | 1/42 | 1/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
| NauseaGastrointestinal disorders | 0/21 | 1/20 | 1/20 | 0/20 | 0/42 | 1/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
| Upper respiratory tract infectionInfections and infestations | 0/21 | 0/20 | 0/20 | 0/20 | 0/42 | 1/17 | 0/349 | 0/352 | 0/361 | 0/72 | 0/71 |
Part A and B: Safety Set - All participants who received at least one dose in of IMP. 35 participants were randomized to Part C - Cohort 9. As per protocol, these participants did not receive treatment.
| Age, Continuous(years) | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A | 35.4 ± 11.13 | 38.7 ± 9.79 | 36.0 ± 11.89 | 39.8 ± 8.53 | 47.5 ± 11.10 | 37.1 ± 11.21 | — | — | — | — | — | — | 40.4 ± 11.61 |
| Part B | — | — | — | — | — | — | 48.1 ± 14.68 | 50.5 ± 15.27 | 42.1 ± 15.91 | — | — | — | 46.9 ± 15.70 |
| Part C | — | — | — | — | — | — | — | — | — | 41.9 ± 12.14 | 43.5 ± 13.57 | 44.5 ± 11.15 | 43.0 ± 12.52 |
| Age, Customized(Participants) | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 to 55 years old | 21 | 20 | 20 | 20 | 42 | 17 | 222 | 210 | 242 | 61 | 60 | 31 | 966 |
| 56 to 85 years old | 0 | 0 | 0 | 0 | 0 | 0 | 127 | 142 | 119 | 11 | 11 | 4 | 414 |
| Sex: Female, Male(Participants) | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 11 | 12 | 10 | 13 | 14 | 11 | 169 | 161 | 204 | 42 | 43 | 25 | 715 |
| Male | 10 | 8 | 10 | 7 | 28 | 6 | 180 | 191 | 157 | 30 | 28 | 10 | 665 |
| Race/Ethnicity, Customized(Participants) | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 4 |
| Asian | 0 | 1 | 1 | 1 | 4 | 0 | 10 | 6 | 0 | 4 | 4 | 1 | 32 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Black or African American | 0 | 0 | 0 | 0 | 3 | 6 | 50 | 8 | 242 | 4 | 7 | 2 | 322 |
| White | 20 | 18 | 19 | 19 | 35 | 11 | 258 | 330 | 15 | 62 | 59 | 31 | 877 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 63 | 0 | 0 | 0 | 66 |
| Multiracial | 0 | 0 | 0 | 0 | 0 | 0 | 30 | 3 | 41 | 0 | 1 | 0 | 75 |
| Not reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Hispanic or Latino | 7 | 3 | 9 | 1 | 5 | 5 | 30 | 55 | 10 | 12 | 5 | 5 | 147 |
| Not Hispanic or Latino | 14 | 17 | 11 | 19 | 37 | 12 | 317 | 294 | 348 | 59 | 66 | 30 | 1224 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 3 | 1 | 0 | 0 | 9 |
| Region of Enrollment(participants) | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turkey | 0 | 0 | 0 | 0 | 0 | 0 | 137 | 0 | 0 | 0 | 0 | 0 | 137 |
| United States | 21 | 20 | 20 | 20 | 42 | 17 | 134 | 284 | 23 | 62 | 62 | 32 | 737 |
| South Africa | 0 | 0 | 0 | 0 | 0 | 0 | 78 | 4 | 338 | 0 | 0 | 0 | 420 |
| Germany | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 64 | 0 | 10 | 9 | 3 | 86 |
| Body Mass Index (BMI)(kg/m^2) | Part A - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7) | Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2) | Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2) | Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2) | Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529) | Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine) | Part C - Cohort 9: No Vaccination | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A | 27.54 ± 5.508 | 27.97 ± 6.840 | 30.09 ± 6.509 | 29.72 ± 6.287 | 29.83 ± 6.722 | 30.82 ± 8.394 | — | — | — | — | — | — | 29.35 ± 6.663 |
| Part B | — | — | — | — | — | — | 28.29 ± 6.012 | 28.78 ± 6.202 | 26.30 ± 8.413 | — | — | — | 27.77 ± 7.065 |
| Part C | — | — | — | — | — | — | — | — | — | 29.25 ± 6.648 | 28.60 ± 6.581 | 30.23 ± 5.133 | 29.18 ± 6.346 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Aug 2023, 23 months.
Results were first posted in Nov 2024, 1 year 3 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 23 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine